Study Group: Surgeons who Perform Lap-Band Procedures
Council Members in this Study Group: 32
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
Carlos DujovneProfessor of Medicine and Director
OREGON HEALTH & SCIENCE UNIVERSITY - CC
Carlos Dujovne is the Professor of Medicine, the Chairman of Kansas Foundation for Clinical Pharmacology and Therapeutics (KFCPT), Cardiovascular Division and the Director of Clinical Cardiovascular and Metabolic Risk Treatment Programs at Oregon Health...
- Howard Beaton
Associate Professor of Surgery
Mount Sinai Medical Center (NY)Howard Beaton, MD, is an Attending Surgeon and Associate Professor of Surgery at the Mount Sinai Medical Center in New York City. Previously, he was the Chairman of Surgery at North General and NYU Downtown Hospitals. Dr. Beaton has over 25 years of experience...
Elliot GoodmanChief of Bariatric Surgery
BETH ISRAEL MEDICAL CENTER (INC)Elliot Goodman, MD, is Chief of Bariatric Surgery at Beth Israel Medical Center and Assistant Professor of Surgery at Albert Einstein College of Medicine in New York City. His main clinical interest is bariatric surgery. His research interests include...
- Forrest Rubenstein
Cardiac, Thoracic and Vascular Surgeon
Rubenstein Cardiovascular and Thoracic SurgeryForrest Rubenstein, MD, FACS, is a Cardiac, Thoracic and Vascular Surgeon in private practice. Dr. Rubenstein is board certified in General, Cardiovascular and Thoracic Surgery. He has experience in cardiac, thoracic and vascular surgery, aortic surgery,...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
November 13, 2008
CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study | www.astrazeneca.com
1:Crestor is the most potent statin in the market,yet is 3d in sales behind Zocor and Lipitor.2:The efficacy supriority together with its capacity to lower CRP levels led to the highest rate of ASCVD prevention in the shortest period of time evr documented in statin trials.3:The trial in near 18,000 patients with otherwise lower risk of ASCVD offered $0% reduction y many ascvd endpoints.4:There were no statistical differences in side effect compared to placebo.5:The dosage was 20 mg /day (an intermediate dose below the approved max dose of 40 mg/day
-
September 29, 2008
Many Trial Reports on FDA-Approved Drugs Go Unpublished | www.washingtonpost.com
This article is not news for clinical researchers like myself that have performed hundreds of clinical trials in collaboration with the Pharmaceutical Industry. Some of the most common reasons for that are: A)Negative studies are difficult to get published.B)Negative results for the dug of the sponsor company are of potentially damaging financial for the sponsor.C)There is no FDA regulation that prohibits a sponsor to deny access to data and freedom of publication to Investigators of the trial not employed by them. Some of the possible solutions for these problems are:A)Complete freedom of access and publication of data by investigators.B)Sponsors of studies be obligated to submit result regardless of outcome,to FDA.C)Studies shall be easily searchable in a Google style manner at FDA files,by naming a company ,a drug ,a condition,etc,etc.
-
June 23, 2008
After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 | newsroom.lilly.com
More than 50% of patients have the 3 ccomponents to qualify for diagnosis of Metabolic Syndrome.Twwo of the components,Diabetes and Obesity are present in 20-25% of them and are difficult to control.Exenatide seems to provide that benefit.
-
February 19, 2008
China Plant Played Role | online.wsj.com
1:Most of our legislators are forcefully endorsing generic drug usage and importing cheaper drugs.2:As a physician specialist in Clinical Pharmacologist I am fully aware or the safety and efficacy pitfalls of poorly manufactured drugs and have done clinical research documenting the risks of patients treated with them.3:For that reason I strongly advised my patients to buy branded drugs by reputable Pharmaceutical Companies who have much to loose if found to manufacture poorly made drugs.
-
Preventing Bariatric Surgery Deaths
January 25, 2008
Pinning Down Mortality Rates After Bariatric Surgery | www.medscape.com
Bariatric surgery is a major operative procedure that caries significant morbidity and mortality risks due to the comorbid diseases seen in this patient population. This procedure is increasing in frequency as more patients are willing to have it and more surgeons are becoming proficient. The mortality rate is ~ 1 % at 1 year and 6% at 5 years which is greater than the population at large.
Members in this Study Group include these company types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
- Temporary Staffing Services
- Free-standing Surgery Center
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Physician - Director
- Physician - Division Head
- Owner
- Director
- President
- Consultant
- Partner